HC Wainwright Has Lowered Expectations for Bicara Therapeutics (NASDAQ:BCAX) Stock Price

Bicara Therapeutics (NASDAQ:BCAX) had its target price lowered by equities research analysts at HC Wainwright from $44.00 to $41.00 in a report issued on Friday,Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s target price indicates a potential upside of 183.34% from the stock’s current price. HC Wainwright also issued estimates for Bicara Therapeutics’ FY2026 earnings at ($2.59) EPS.

Several other brokerages have also issued reports on BCAX. Stifel Nicolaus set a $48.00 target price on Bicara Therapeutics in a research report on Thursday, March 27th. Wells Fargo & Company assumed coverage on Bicara Therapeutics in a research note on Thursday, April 17th. They issued an “underweight” rating and a $8.00 target price for the company. Wedbush restated an “outperform” rating and issued a $31.00 target price on shares of Bicara Therapeutics in a research note on Thursday, March 27th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $13.01 target price on shares of Bicara Therapeutics in a research note on Thursday, March 13th. One research analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $32.00.

Bicara Therapeutics Stock Performance

Shares of BCAX opened at $14.47 on Friday. Bicara Therapeutics has a 52 week low of $8.91 and a 52 week high of $28.09. The stock has a fifty day moving average of $12.81 and a 200-day moving average of $15.25.

Bicara Therapeutics (NASDAQ:BCAX) last announced its quarterly earnings results on Tuesday, May 13th. The company reported ($0.68) EPS for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.28). Sell-side analysts predict that Bicara Therapeutics will post -2.59 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Bicara Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the stock. XTX Topco Ltd boosted its stake in Bicara Therapeutics by 4.1% during the 1st quarter. XTX Topco Ltd now owns 28,453 shares of the company’s stock valued at $371,000 after purchasing an additional 1,119 shares during the last quarter. California State Teachers Retirement System acquired a new position in Bicara Therapeutics during the 4th quarter valued at about $25,000. Spire Wealth Management acquired a new position in Bicara Therapeutics during the 4th quarter valued at about $31,000. BNP Paribas Financial Markets bought a new position in shares of Bicara Therapeutics during the 4th quarter worth approximately $32,000. Finally, Legal & General Group Plc bought a new position in shares of Bicara Therapeutics during the 4th quarter worth approximately $33,000.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.